XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Reportable Segment Information

Reportable segment information was as follows:

			Three Months Ended												Nine Months Ended
			September 30,												September 30,
(DOLLARS IN MILLIONS)			2024						2023						2024						2023
Net sales:
Nourish			$	1,486					$	1,449					$	4,460					$	4,666
Health & Biosciences			570						518						1,659						1,553
Scent			613						615						1,861						1,815
Pharma Solutions			256						238						733						742
Consolidated			$	2,925					$	2,820					$	8,713					$	8,776
Segment Adjusted Operating EBITDA:
Nourish			$	206					$	178					$	654					$	567
Health & Biosciences			173						150						497						426
Scent			127						131						421						353
Pharma Solutions			62						47						162						173
Total			568						506						1,734						1,519
Depreciation & Amortization			(248)						(292)						(772)						(855)
Interest Expense			(74)						(90)						(236)						(291)
Other (Expense) Income, net			(28)						9						(44)						17
Restructuring and Other Charges a)			(1)						(2)						(6)						(61)
Impairment of Goodwill b)			—						—						(64)						—
Gains (Losses) on Business Disposals c)			(20)						(10)						348						(29)
Loss on Assets Classified as Held for Sale d)			(32)						—						(314)						—
Acquisition, Divestiture and Integration Costs e)			(55)						(42)						(172)						(118)
Strategic Initiatives Costs f)			(6)						(6)						(22)						(28)
Regulatory Costs g)			(10)						(13)						(64)						(32)
Other h)			1						(1)						5						1
Income Before Taxes			$	95					$	59					$	393					$	123

_______________________

a)			For 2024, represents costs related to lease impairment and severance as part of the Company's restructuring efforts. For 2023, represents costs primarily related to severance as part of the Company's restructuring efforts.
b)			For 2024, represents costs related to the impairment of goodwill related to the Pharma Solutions disposal group.

c)			For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business and losses recognized as part of the sale of the F&E UK business. For 2023, primarily represents losses recognized as part of the sale of the Flavors Specialty Ingredients business, the sale of a portion of the Savory Solutions business, and liquidation of a business in Russia for the sale of the portion of the Savory Solutions business.
d)			For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group and portion of the Savory Solutions business in Turkey.
e)			For 2024 and 2023, primarily represents costs related to the Company's actual and planned acquisitions and divestitures and integration related activities primarily for N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For the three months ended September 30, 2024, business divestiture costs were approximately $55 million. For the three months ended September 30, 2023, business divestiture, integration and acquisition costs were approximately $29 million, $12 million and $1 million, respectively. For the nine months ended September 30, 2024, business divestiture and integration costs were approximately $167 million and $5 million, respectively. For the nine months ended September 30, 2023, business divestiture, integration and acquisition costs were approximately $70 million, $42 million, and $6 million, respectively.
f)			Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees.
g)			Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.
h)			Represents gains (losses) from sale of assets, executive employee separation costs and costs related to the Company's entity realignment project to optimize the structure of holding companies, primarily consulting fees.

Net Sales by Destination of Product Delivery

Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows:

			Three Months Ended September 30,												Nine Months Ended September 30,
(DOLLARS IN MILLIONS)			2024						2023						2024						2023
Europe, Africa and Middle East			$	964					$	918					$	2,913					$	2,958
Greater Asia			694						670						2,057						2,031
North America			886						853						2,628						2,668
Latin America			381						379						1,115						1,119
Consolidated			$	2,925					$	2,820					$	8,713					$	8,776

			Three Months Ended September 30,												Nine Months Ended September 30,
(DOLLARS IN MILLIONS)			2024						2023						2024						2023
Net sales related to the U.S.			$	834					$	782					$	2,467					$	2,430
Net sales attributed to all foreign countries			2,091						2,038						6,246						6,346

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration